If Germany approves I could see this trading between $15 and $20.
The report came out yesterday. Anyone read it?
I learned that the hard way. That's the biggest red flag for this stock in my opinion.
The CEO does infomercials. Covered by the notorious redchip. Vsel existence in doubt. Baxter may be pulling the plug on its trial.
Cellular therapy developer Neostem (NBS_) blows up on negative cardiac clinical trial data but CEO Robin Smith restructures company by opening a nationwide chain of stem-cell smoothie shops.